Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Oct;43(10):2565-8.
doi: 10.1128/AAC.43.10.2565.

Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam

M Backo  1 , E Gaenger, A Burkart, Y L Chai, A S Bayer
Affiliations

Treatment of experimental staphylococcal endocarditis due to a strain with reduced susceptibility in vitro to vancomycin: efficacy of ampicillin-sulbactam

M Backo et al. Antimicrob Agents Chemother. 1999 Oct.

Abstract

We evaluated several 3-day antimicrobial regimens in the treatment of experimental endocarditis caused by an oxacillin-resistant Staphylococcus aureus strain exhibiting intermediate susceptibility in vitro to vancomycin (VISA). Neither vancomycin alone nor trovafloxacin exhibited in vivo efficacy; addition of amikacin to vancomycin yielded a modest in vivo effect. In contrast, the combination of ampicillin and sulbactam was highly effective in vivo, causing a mean decrease in VISA vegetation densities of >5 log(10) CFU/g versus those of untreated controls.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Timed-kill curve of VISA MU-50 (inoculum, 106) versus the studied antibiotics, each at five times the MIC. Trova, trovafloxacin; Vanco, vancomycin; Vanco+Amk, vancomycin plus amikacin; A+S, ampicillin plus sulbactam; Control, medium alone. Data points represent the means of results from two independent assays performed on different days.
See this image and copyright information in PMC

References

    1. Bayer A S, Crowell D, Bradley D, Yih J, Norman D C. Differential antimicrobial pharmacokinetics and pharmacodynamics in right-sided versus left-sided vegetations in experimental Pseudomonas aeruginosa endocarditis. J Infect Dis. 1988;158:355–359. - PubMed
    1. Bayer A S, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J Infect Dis. 1985;151:157–165. - PubMed
    1. Bayer A S, Li C, Ing M. Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains. Antimicrob Agents Chemother. 1998;42:1837–1841. - PMC - PubMed
    1. Bayer A S, Norman D C. Valve-site specific pathogenetic differences between right-sided and left-sided bacterial endocarditis. Chest. 1990;98:200–205. - PubMed
    1. Bayer A S, Norman D C, Chiu C Y, Nast C. Pathogenic effects of neutropenia, monocytopenia and steroid treatment in experimental Pseudomonas endocarditis. Chemotherapy. 1989;35:278–288. - PubMed

Publication types

MeSH terms

LinkOut - more resources